| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_70b002124ed40a6e0f18739d736c6cb0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2015-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-285 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N15-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N15-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N15-14 |
| filingDate |
2016-05-19^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-06-30^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2399637940a6e6f219ae2102993c806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cb5c84f44842a06e5246d3dc45f42bfc |
| publicationDate |
2020-06-30^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10697883-B2 |
| titleOfInvention |
Method for determining application of therapy to multiple sclerosis (MS) patient |
| abstract |
According to the present invention, the therapeutic effect of an IL-6 inhibitor on MS was found to be predictable by using as indicators the amount of plasmablasts and/or the indicator of change in immature plasmablasts (amount of immature plasmablasts or amount of follicular helper T cells) in MS patients with a large amount of plasmablasts. Furthermore, IL-6 inhibitors were found to be effective against MS in which plasmablasts occur at high levels and in which the indicator of change in immature plasmablasts is high. The present invention provides methods for selecting MS cases for which treatment with an IL-6 inhibitor is effective, and also provides an effective therapeutic method for patients with MS in which plasmablast occur at high levels and in which the indicator of change in immature plasmablasts is high. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11692037-B2 |
| priorityDate |
2015-05-19^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |